FDA Hands Out Fast-Track Voucher for Kids' Hearing Loss Drug
Published Date: 5/6/2026
Notice
Summary
The FDA just gave Regeneron a special priority review voucher for their new rare pediatric disease treatment, OTARMENI, approved on April 23, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids and adults with severe hearing loss faster. It’s a big win for patients and could save time and money in bringing new treatments to market.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
OTARMENI approved for OTOF hearing loss
You or your child with severe-to-profound sensorineural hearing loss may be eligible for OTARMENI, which the FDA approved on April 23, 2026. The approval covers pediatric and adult patients with any frequency >90 dB HL who have molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-08906 — Automated Commercial Environment (ACE) Export Manifest for Air Cargo Test: Renewal of Test
U.S. Customs and Border Protection is renewing its fun and helpful test that lets air cargo exporters send their shipment info electronically before loading. This test, which started in 2015 and keeps getting extended, will now run for two more years starting May 6, 2026. If you’re involved in air cargo exports, you can join anytime and help shape the future of faster, smoother customs processing—no extra fees involved!
Next: 2026-08933 — Renewal of Department of War Federal Advisory Committee-Department of the Air Force Scientific Advisory Board
The Department of War is renewing the Air Force Scientific Advisory Board to keep getting expert advice on science and technology. This group helps the Air Force stay sharp and innovative, with an annual budget of about $3.9 million. The renewal means the board will keep meeting and advising for the next few years, making sure the Air Force stays ahead in cool tech and defense.